Foghorn Therapeutics (FHTX) Total Debt (2019 - 2021)

Foghorn Therapeutics' Total Debt history runs 3 years deep, the most recent figure standing at $19.9 million for Q3 2021.

• On a quarterly basis, Total Debt rose 34.64% year-over-year to $19.9 million in Q3 2021; TTM through Sep 2021 was $19.9 million, a 34.64% increase from a year earlier, with the FY2020 full-year figure at $19.7 million, up 30.06% from the prior year.
• Total Debt held at $19.9 million in Q3 2021 per FHTX's latest filing, from $19.8 million in the prior quarter.
• Across five years, Total Debt topped out at $19.9 million in Q3 2021 and bottomed at $14.8 million in Q3 2020.
• The 3-year median for Total Debt is $19.7 million (2020), against an average of $18.2 million.
• Across the five-year window, Total Debt soared 30.06% in 2020 and jumped 34.64% in 2021, its largest moves.
• Year by year, Total Debt stood at $15.1 million in 2019, then jumped by 30.06% to $19.7 million in 2020, then advanced by 1.32% to $19.9 million in 2021.
• Per Business Quant, the three latest FHTX Total Debt figures stand at $19.9 million (Q3 2021), $19.8 million (Q2 2021), and $19.7 million (Q1 2021).